60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis

Company Overview

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Key Stats

• Today's Range: $1.25 to $1.39
• 50-Day Range: $0.72 to $2.21
• 52-Week Range: $0.70 to $15.00
• Volume: 132,862 shs
• Average Volume: 285,692 shs
• Market Capitalization: $3.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

60 Degrees Pharmaceuticals Stock Analysis - MarketRank™

60 Degrees Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for 60 Degrees Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 60 Degrees Pharmaceuticals are expected to grow in the coming year, from ($5.09) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 60 Degrees Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 60 Degrees Pharmaceuticals is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.85% of the float of 60 Degrees Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 60 Degrees Pharmaceuticals has recently increased by 412.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

60 Degrees Pharmaceuticals does not currently pay a dividend.

Dividend Growth

60 Degrees Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

13.85% of the float of 60 Degrees Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in 60 Degrees Pharmaceuticals has recently increased by 412.33%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.58

News Sentiment

60 Degrees Pharmaceuticals has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for 60 Degrees Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

3 people have searched for SXTP on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added 60 Degrees Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, 60 Degrees Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $82,410.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.27% of the stock of 60 Degrees Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 7.96% of the stock of 60 Degrees Pharmaceuticals is held by institutions.

SXTP Stock Analysis - Frequently Asked Questions

How have SXTP shares performed this year?

60 Degrees Pharmaceuticals' stock was trading at $1.02 at the start of the year. Since then, SXTP shares have increased by 29.9% and is now trading at $1.3252.
View the best growth stocks for 2024 here.

How were 60 Degrees Pharmaceuticals' earnings last quarter?

60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) posted its quarterly earnings results on Wednesday, August, 14th. The company reported ($4.23) earnings per share for the quarter, missing analysts' consensus estimates of ($2.79) by $1.44. The firm earned $0.13 million during the quarter, compared to the consensus estimate of $0.11 million.

When did 60 Degrees Pharmaceuticals IPO?

60 Degrees Pharmaceuticals (SXTP) raised $7 million in an IPO on Wednesday, July 12th 2023. The company issued 1,400,000 shares at a price of $5.30 per share. WallachBeth Capital LLC served as the underwriter for the IPO.

How do I buy shares of 60 Degrees Pharmaceuticals?

Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of 60 Degrees Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 60 Degrees Pharmaceuticals investors own include Recursion Pharmaceuticals (RXRX), Editas Medicine (EDIT), Pacific Biosciences of California (PACB), Tilray (TLRY), Akanda (AKAN), Better Therapeutics (BTTX) and Honeywell International (HON).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 12/26/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SXTP
• CUSIP: N/A
• CIK: 1946563
• Web: 60degreespharma.com
• Phone: 202-327-5422
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($10.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,770,000.00
• Net Margins: N/A
• Pretax Margin: -16,230.61%
• Return on Equity: N/A
• Return on Assets: -113.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.26
• Quick Ratio: 4.92

Sales & Book Value

• Annual Sales: $502,409.00
• Price / Sales: 6.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($10.45) per share
• Price / Book: -0.13

Miscellaneous

• Outstanding Shares: 2,297,000
• Free Float: 2,061,000
• Market Cap: $3.12 million
• Optionable: Not Optionable
• Beta: 5.36